Cyclacel Historical Income Statement
| CYCC Stock | USD 0.36 0.01 2.86% |
Historical analysis of Cyclacel Pharmaceuticals income statement accounts such as Interest Expense of 2.4 M, Selling General Administrative of 5.9 M or Total Revenue of 549.3 K can show how well Cyclacel Pharmaceuticals performed in making a profits. Evaluating Cyclacel Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cyclacel Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cyclacel Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cyclacel Pharmaceuticals is a good buy for the upcoming year.
Cyclacel |
About Cyclacel Income Statement Analysis
Cyclacel Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cyclacel Pharmaceuticals shareholders. The income statement also shows Cyclacel investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cyclacel Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cyclacel Pharmaceuticals. It is also known as Cyclacel Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Cyclacel Pharmaceuticals income statement and is an important metric when analyzing Cyclacel Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from Cyclacel Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cyclacel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.At present, Cyclacel Pharmaceuticals' Total Revenue is projected to decrease significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 408.4 K, whereas Depreciation And Amortization is forecasted to decline to about 29.4 K.
| 2023 | 2024 (projected) | Discontinued Operations | 17.1K | 30.4K | Cost Of Revenue | 31K | 29.5K |
Cyclacel Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Cyclacel Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclacel Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (101K) | 20K | 43K | (233K) | 31K | 29.5K | |
| Interest Expense | 677K | 997K | 291K | 2.0M | 2.3M | 2.4M | |
| Selling General Administrative | 5.0M | 5.9M | 7.5M | 7.4M | 6.7M | 5.9M | |
| Gross Profit | (32K) | (4.2M) | (20K) | (43K) | 389K | 408.5K | |
| Other Operating Expenses | 9.7M | 10.6M | 22.9M | 27.7M | 25.9M | 16.3M | |
| Operating Income | (9.7M) | (10.6M) | (22.9M) | (27.7M) | (25.5M) | (26.7M) | |
| Ebit | (9.7M) | (10.6M) | (22.7M) | (27.7M) | (25.5M) | (26.7M) | |
| Research Development | 4.7M | 4.8M | 15.5M | 20.3M | 19.2M | 20.1M | |
| Ebitda | (9.8M) | (10.6M) | (22.7M) | (27.9M) | (25.4M) | (26.7M) | |
| Total Operating Expenses | 9.7M | 10.6M | 22.9M | 27.7M | 25.9M | 14.8M | |
| Income Before Tax | (9.1M) | (9.7M) | (22.7M) | (25.9M) | (25.6M) | (26.8M) | |
| Total Other Income Expense Net | 556K | 955K | 204K | 1.7M | (98K) | (102.9K) | |
| Net Income | (7.8M) | (8.4M) | (18.9M) | (21.2M) | (22.6M) | (23.7M) | |
| Income Tax Expense | (1.3M) | (1.2M) | (3.8M) | (4.7M) | (3.0M) | (2.8M) | |
| Cost Of Revenue | 32K | 4.3M | 20K | 43K | 31K | 29.5K | |
| Net Income From Continuing Ops | (7.8M) | (8.4M) | (18.9M) | (21.2M) | (24.7M) | (23.5M) | |
| Non Operating Income Net Other | 1.0M | 923K | 556K | (2.8M) | (2.5M) | (2.4M) | |
| Net Income Applicable To Common Shares | (8.0M) | (8.6M) | (19.1M) | (21.4M) | (24.6M) | (25.8M) | |
| Tax Provision | (1.3M) | (1.2M) | (3.8M) | (4.7M) | (4.2M) | (3.9M) | |
| Interest Income | 224K | 42K | 16K | 210K | 365K | 383.3K | |
| Net Interest Income | 224K | 42K | 16K | 210K | 365K | 184.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.40) | Revenue Per Share 0.044 | Quarterly Revenue Growth (0.99) | Return On Assets (1.03) | Return On Equity (5.71) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.